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BISPHENOL A (BPA) IS ONE OFthe world’s highest produc-tion–volume chemicals, withmore than 2 million metric
tons produced worldwide in 2003 and
annual increase in demand of 6% to
10% annually.1 Bisphenol A is used ex-
tensively in epoxy resins lining food and
beverage containers and as a mono-
mer in polycarbonate plastics in many
consumer products. Widespread and
continuous exposure to BPA, primar-
ily through food but also through drink-
ing water, dental sealants, dermal ex-
posure, and inhalation of household
dusts, is evident from the presence of
detectable levels of BPA in more than
90% of the US population.2-4
Most studies of the health effects of
BPA have focused on well-documented
estrogenic activity,5 but reports have
highlighted additional modes of ac-
tion,6 including liver damage,7-11 dis-
rupted pancreatic -cell function,12
thyroid hormone disruption,13 and obe-
sity-promoting effects.14 The potential for
low-dose effects15 has added to the con-
troversy about possible hazards and
whether currently recommended expo-
sure thresholds require revision.16-19
Debateabout thehealtheffectsofBPA
inhumanshasbeenhinderedbythe lack
of epidemiologic data of sufficient sta-
tisticalpower todetect low-doseeffects.4
The US National Health and Nutrition
Examination Survey (NHANES) 2003-
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Context Bisphenol A (BPA) is widely used in epoxy resins lining food and beverage
containers. Evidence of effects in animals has generated concern over low-level chronic
exposures in humans.
Objective To examine associations between urinary BPA concentrations and adult
health status.
Design, Setting, and Participants Cross-sectional analysis of BPA concentra-
tions and health status in the general adult population of the United States, using data
from the National Health and Nutrition Examination Survey 2003-2004. Participants
were 1455 adults aged 18 through 74 years with measured urinary BPA and urine
creatinine concentrations. Regression models were adjusted for age, sex, race/
ethnicity, education, income, smoking, bodymass index, waist circumference, and uri-
nary creatinine concentration. The sample provided 80% power to detect unadjusted
odds ratios (ORs) of 1.4 for diagnoses of 5% prevalence per 1-SD change in BPA con-
centration, or standardized regression coefficients of 0.075 for liver enzyme concen-
trations, at a significance level of P .05.
Main Outcome Measures Chronic disease diagnoses plus blood markers of liver
function, glucose homeostasis, inflammation, and lipid changes.
Results Higher urinary BPA concentrations were associated with cardiovascular diag-
noses in age-, sex-, and fully adjusted models (OR per 1-SD increase in BPA concentra-
tion, 1.39; 95%confidence interval [CI], 1.18-1.63; P=.001with full adjustment). Higher
BPA concentrationswere also associatedwith diabetes (ORper 1-SD increase in BPA con-
centration, 1.39; 95% confidence interval [CI], 1.21-1.60; P .001) but not with other
studied common diseases. In addition, higher BPA concentrations were associated with
clinically abnormal concentrations of the liver enzymes -glutamyltransferase (OR per
1-SD increase in BPA concentration, 1.29; 95%CI, 1.14-1.46;P.001) and alkaline phos-
phatase (OR per 1-SD increase in BPA concentration, 1.48; 95%CI, 1.18-1.85; P=.002).
Conclusion HigherBPAexposure, reflected inhigherurinaryconcentrationsofBPA,may
be associated with avoidable morbidity in the community-dwelling adult population.
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2004 recently released the only large-
scale data on urinary BPA concentra-
tions.20 BecauseorallyadministeredBPA
israpidlyandcompletelyexcreted,urine
is considered thebody fluidmostappro-
priate for assessmentofBPAexposure.21
The highly water-soluble major BPA
metabolite, BPA-monoglucuronide, is
formed in the gut wall and liver and is
rapidly removed from the blood by the
kidneys, with terminal half-lives of less
than 6 hours after oral administration.21
Given the previous animal evidence,
we hypothesized that higher urinary BPA
concentrations would be associated with
adverse health effects, especially in the
liver and in relation to insulin, type 2 dia-
betes, and obesity in humans. Because of
the paucity of direct human evidence,
however, we undertook analyses of all
8 of the reported major diagnostic group-
ings available in the NHANES 2003-
2004 data (including cardiovascular and
respiratory conditions for which 3 ques-
tions each are available on subdiagno-
ses). We also examined a preselected list
of 8 blood-based clinical measures re-
flecting liver function, glucose homeo-
stasis, inflammation, and lipid changes.
METHODS
Data were from NHANES 2003-2004.22
NHANES surveys assess the health and
diet of the noninstitutionalized US popu-
lation and are administered by the
National Center for Health Statistics.
NHANES was approved by the Na-
tional Centers for Health Statistics insti-
tutional review board, and all partici-
pants provide written informed consent.
Assessment of BPA Concentrations
NHANES includes biomonitoring for ex-
posure to a range of environmental tox-
ins.23 A one-third random subset of
NHANES 2003-2004 participants sup-
plied urine samples that were then ana-
lyzed for BPA concentration. A spot
urine sample was collected from each
participant. Total (free and conju-
gated) urinary concentrations of BPA
were measured at the Division of Envi-
ronmental Health Laboratory Sciences
(National Center for Environmental
Health, Centers for Disease Control and
Prevention) using online solid-phase
extraction coupled with high-perfor-
mance liquid chromatography– isotope-
dilution tandem mass spectrometry with
peak focusing. A comprehensive qual-
ity control system, including reagent
blanks, was used to ensure that samples
were not contaminated during han-
dling, storage, and analysis.24 For
BPA concentrations below the level of
detection (116/1455 [8%]), a value of
0.3 ng/mL was assigned by NHANES; we
used this value in our analyses.
Health Outcomes
Participantsaged20yearsandolderwere
asked “Has a doctor or other health pro-
fessionalevertoldyouthatyouhave . . . .”
for angina, arthritis, asthma, cancer,
chronic bronchitis, coronary heart dis-
ease, emphysema, heart attack, liver dis-
ease (any kind), stroke, or thyroid dis-
ease.Participants18yearsandolderwere
askedaboutasthmaanddiabetes.Because
of lownumbers,emphysema(n=20)was
combinedwithchronicbronchitis. Simi-
larly, we combined diagnosed and bor-
derline diabetes and grouped the cardio-
vascular conditions (reported angina,
coronaryheartdisease, andheart attack).
We included all available common con-
ditions (ie, those with40 cases) in the
analyses, covering 8 major disease cat-
egories after grouping.
We analyzed concentrations of the
following 8 blood serum analytes: C-
reactive protein, quantified using latex-
enhanced nephelometry; -glutamyl-
transferase (GGT), using an enzymatic
ratemethod;lactatedehydrogenase,using
anenzymaticratemethod;alkalinephos-
phatase, using a 2-amino-2-methyl-1-
propanolbuffer; triglycerides,measured
enzymatically followinghydrolysis; low-
density lipoproteincholesterol(LDL-C),
calculated from measured values of
total cholesterol, triglycerides, andhigh-
density lipoprotein cholesterol; fasting
glucose,usingspectrophotometricmea-
surement of reduced nicotinamide ad-
enine dinucleotide concentration; and
fasting insulin, using a 2-site immuno-
enzymometric assay. Details of analyte
extractionandmeasurementareavailable
athttp://www.cdc.gov/nchs/nhanes.htm.
Two derived glucose homeostasis in-
dices were used: steady-state-cell func-
tion, calculated from fasting levels of glu-
cose and insulin using the computerized
version of the updated homeostasis
model assessment (HOMA2),25 and
HOMA2 insulin resistance, the recipro-
cal of insulin sensitivity, also calculated
using the HOMA2 model.
Statistical Analysis
NHANES 2003-2004 used a complex
cluster sample design, with some demo-
graphic groups (including Mexican
Americans and groups in low socioeco-
nomic positions) oversampled to ensure
adequate representation. To account for
this complex sampling, weighted esti-
mates of population parameters were
computed, following the NHANES Ana-
lytic and Reporting Guidelines (Septem-
ber 2006). For most analyses, popula-
tion weights for the BPA measurement
sample (subsample C of the medical
examination)wereused.Samplingerrors
were estimated by the Taylor series (lin-
earization) method to account for strati-
fication and clustering using the pro-
vided“maskedvariancepseudo-psu”and
“pseudo-stratum” variables. This pro-
cedure produced the same geometric
mean and variance estimates as those
published by the National Center for
Environmental Health3 (ie, geometric
mean BPA concentrations for age group
20 to 59 years, 2.6 µg/L; 95% confi-
dence interval [CI], 2.3 to 2.9). Data on
levels of LDL-C, glucose, and insulin
were available in a random subsample
assigned to fast (n=653); for theseanaly-
ses, a specific fasting specimen weight
was used as directed. Analyses were con-
ducted by 3 authors (I.A.L., W.E.H.,
D.M.) using Stata SE version 9.2 (Stata-
Corp, College Station, Texas); P .05
was considered statistically significant.
Using the sample weights in a classi-
cal design-based analysis of survey data
provides asymptotically unbiased esti-
mates of population parameters but can
lead to inefficiency (ie, inflation of stan-
dard errors).26 An overall inefficiency
coefficient of 34% was calculated for our
NHANES 2003-2004 BPA data set using
equation 3.7 in Korn and Graubard.26
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To assess the sensitivity of our findings
to the weighting method, we repeated
all analyses using a partial weighting
approach in which the unweighted
regression model was augmented with
exogenous design variables.26 There
were no substantive changes in the
model inferences (see eSupplement at
http://www.jama.com).
Because the diseases of interest are rare
in children, we restricted our analyses to
respondents aged 18 through 74 years (of
those randomly selected by NHANES
2003-2004 for measurement of BPA con-
centration) to focus on health effects in
adults. The upper age cutoff was cho-
sen to minimize problems of comorbid-
ity and nonrepresentation of seniors in
institutions. We excluded 1 respondent
because of a missing urinary creatinine
concentration, resulting in an included
sample of 1455 respondents.
We used logistic regression to esti-
mate odds ratios (ORs) of physician-
diagnosed diseases (as the dependent
variable) per 1-SD increase in BPA con-
centrations and used linear regression
to estimate associations between logged
levels of blood analytes and standard-
ized BPA concentrations.
Regression models were adjusted for
a broad range of potential confounders,
including socioeconomic factors that
Calafat et al3 have shown to be associ-
ated with BPA and urinary creatinine
concentrations.27 Variables includedwere
race/ethnicity (from self-description and
categorized into Mexican American,
other Hispanic, non-Hispanic white,
non-Hispanic black, and other race [in-
cluding multiracial]); education (cat-
egorized as high school, high school
diploma [including General Educa-
tionalDevelopment], andhighschool);
annual household income (in 3 approxi-
matelyequal-sizedcategories [$25 000,
$25 000-$55 000, and $55 000], plus
a fourth category for missing values
[n=92]); smoking (from self-reported
status and categorized as never smoked,
former smoker, smoking some days, and
smoking every day, plus unknown, be-
cause the questions were asked of those
aged20 years [n=177]); body mass in-
dex (BMI) (calculated as weight in kilo-
grams divided by height in meters
squared and categorized as under-
weight [18.5], recommended weight
[18.5-24.9], overweight [25.0-29.9],
obese I [30.0-34.9], or obese II [35.0],
with a final category for participants with
missing values [n=25]); waist circum-
ference (in quintiles, with n=60 in a
group with missing values); and uri-
nary creatinine concentration in mg/dL.
We carried out 5 sets of sensitivity
analyses, which were identified post hoc
to test the robustness of our findings.
First, to assess whether increased levels
of liver enzymes reflect normal induc-
tion of enzymes or a clinically relevant
abnormality, we used NHANES refer-
ence ranges, established from wellness
participants with an age mix similar to
that of NHANES participants. Ranges
were 36 to 113 U/L for alkaline phos-
phatase, 93 to 198 U/L for lactate dehy-
drogenase, and 10 to 65 U/L for GGT in
men and 8 to 36 U/L in women (to con-
vert values for all 3 analytes to µkat/L,
multiply by 0.0167).28 Second, to inves-
tigate whether the presence of the dis-
eases found to be associated with BPA
concentrations might have been associ-
ated with altered BPA exposure (per-
haps through greater consumption of
sugar-free foods or drinks from plastic
containers by individuals trying to man-
age their obesity or diabetes), we exam-
ined associations of BPA with increased
levels of liver enzymes in respondents in
2subgroups: those reportingneithercar-
diovascular disease nor diabetes, and
those with BMI less than 25. Third,
because alcohol intake might confound
associations of BPA concentration with
increased levelsof liverenzymes,wecon-
ducted our analyses again including data
on self-reported daily alcohol consump-
tion. Fourth,we testedwhether theasso-
ciation between BPA concentrations and
cardiovascular disease was robust to
adjustment for the effects of lipid levels
(LDL-C and triglycerides). Fifth, to
explore the possibility that our findings
were due to higher exposure to a wider
setofxenoestrogeniccompoundsandnot
specific to BPA concentrations, we
repeated our models including other
known xenoestrogenic compounds.
We also have explored a range of al-
ternative approaches to accounting for
the sampling design, the skewed dis-
tribution of BPA concentrations, and the
correction of urinary creatinine con-
centrations (see eSupplement at http:
//www.jama.com).
Power Calculations
Power calculations for presence of di-
agnoses were conducted using the ap-
proach proposed by Hsieh et al29 for
simple logistic regression models. For
continuous outcomes, the power cal-
culations were performed using the PS
power and sample size program.30,31 The
sample provided 80% power to detect
unadjusted ORs of 1.4 for diagnoses of
5% prevalence per 1-SD change in BPA
concentration (or, for 10% preva-
lence, unadjusted ORs of 1.3). For liver
enzymes and insulin, the detectable
effect sizes for 80% power are given by
standardized regression coefficients of
0.075 and 0.11, respectively.
RESULTS
The study sample included 694 men and
761 women (TABLE1). Weighted but un-
adjusted mean urinary BPA concentra-
tions were similar by sex, but for some
variables ranges were wider. For ex-
ample, mean BPA concentrations in par-
ticipants at recommended weight (BMI
18.5-24.9) were 3.91 ng/mL (95% CI,
3.34 to 4.48), compared with 6.93 ng/mL
(95% CI, 4.39 to 9.47) in those in the
obese II category (BMI35).
Weighted mean BPA concentrations
adjusted for age and sex (FIGURE) ap-
peared higher in those who reported di-
agnoses of cardiovascular diseases (in-
cluding coronary heart disease, heart
attack, and angina) and diabetes. To ex-
plore this further, we estimated the ORs
of reporting a diagnosis of these con-
ditions by z scores of BPA concentra-
tion, using adjusted logistic regres-
sion models including age, sex, and
urinary creatinine concentrations and
fully adjusted models including these
covariates plus race/ethnicity, educa-
tion, income, smoking, BMI, and waist
circumference (TABLE 2). Overall, pat-
terns of linear association in all mod-
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els were similar to those in the Figure.
A 1-SD increase in BPA concentration
was associated with increased ORs of
reporting cardiovascular disease (an-
gina, coronary heart disease, or heart
attack combined) (OR, 1.39; 95% CI,
1.18 to 1.63; P=.001 with full adjust-
ment) and diabetes (OR, 1.39; 95% CI,
1.21 to 1.60; P .001). Associations
with the individual cardiovascular di-
agnoses were all significant. No asso-
ciations with the other diagnoses were
observed.
When using an alternative exposure
metric of dividing BPA concentrations
into quartiles in the fully adjusted mod-
els, participants in the highest BPA con-
centration quartile had an OR of 2.89
(95% CI, 1.07 to 7.78; P=.04) for car-
diovascular disease compared with those
in the lowest quartile. Similarly, those in
the highest BPA concentration quartile
had an OR of 2.43 (95% CI, 1.35 to 4.38;
P=.006) for diabetes compared with
those in the lowest quartile.
TABLE 3 presents results of adjusted
regression models of logged levels of
blood analytes by z scores of BPA con-
centration. In fully adjusted models,
associations were observed between
BPA concentrations and logged levels
of alkaline phosphatase (P=.01), lac-
tate dehydrogenase (P=.04), and GGT
(P= .001). Initial associations (ad-
justed for age, sex, and urinary creati-
nine level) with levels of C-reactive pro-
tein disappeared on further adjustment.
Levels of fasting glucose and insulin
were associated with BPA concentra-
tion in models adjusted for age, sex, and
urinary creatinine concentration but not
in models with full adjustment. No as-
sociations with levels of LDL-C or tri-
glycerides were observed.
Sensitivity Analyses
We first reran our models to assess the
ORs for having clinically above-normal
concentrations of each of the liver en-
zymes. In adjusted models, we found that
a 1-SD increase in BPAconcentrationwas
associated with clinically above-normal
concentrations of GGT (n=129 above
normal; weighted 8.8% prevalence; OR,
1.29; 95% CI, 1.14 to 1.46;P .001), al-
kaline phosphatase (n=58 above nor-
mal;weighted2.6%prevalence;OR,1.48;
95% CI, 1.18 to 1.85; P=.002), and lac-
tate dehydrogenase (n=20 above nor-
mal; 1% prevalence; OR, 1.40; 95% CI,
0.96 to 1.72; P=.08).
In participants reporting neither car-
diovascular disease nor diabetes (exclud-
ing n=190), BPA concentration re-
mained associated with clinically
abnormal concentrations of lactate de-
hydrogenase (OR per 1-SD increase in
BPA concentration, 1.31; 95% CI, 1.06
to 1.62; P=.01) and GGT (OR per 1-SD
increase in BPA concentration, 1.22; 95%
CI, 1.02 to 1.45; P=.03). In those with
BMI less than 25 (n=501), BPA concen-
tration was associated with increased
concentrationsofGGT(=0.09;95%CI,
0.01 to 0.18; P=.03).
Models including measures of alco-
hol consumption included a smaller
Table 1. Sample Characteristics Including Mean Bisphenol A Concentrations (N = 1455)
Characteristic
Unweighted,
No.
Weighted
Percentage
of Samplea
Mean BPA
Concentration
(95% CI), ng/mL
Sex
Men 694 48.2 4.53 (3.98 to 5.08)
Women 761 51.8 4.66 (3.67 to 5.65)
Age group, y
18-29 449 23.5 5.69 (4.74 to 6.64)
30-39 244 20.4 4.38 (3.20 to 5.57)
40-49 252 22.8 4.17 (3.18 to 5.16)
50-59 182 17.7 4.98 (3.85 to 6.12)
60-74 328 15.7 3.41 (2.41 to 4.41)
Race/ethnicity
Mexican American 324 8.5 4.45 (3.48 to 5.41)
Other Hispanic 57 4.3 4.74 (2.86 to 6.62)
Non-Hispanic white 690 69.2 4.45 (3.73 to 5.17)
Non-Hispanic black 313 11.6 6.50 (5.45 to 7.55)
Other (including multiracial) 71 6.4 2.83 (2.03 to 3.63)
Level of education
Less than high school diploma 430 18.1 5.00 (3.99 to 6.00)
High school diploma (including GED) 356 25.9 4.91 (4.02 to 5.80)
Some college education 669 56.1 4.32 (3.57 to 5.07)
Household annual income
$25 000 457 21.8 5.38 (4.19 to 6.58)
$25 000-$55 000 457 32.2 5.25 (4.38 to 6.11)
$55 000 449 41.0 3.72 (3.08 to 4.37)
Unknown 92 5.0 4.11 (2.51 to 5.71)
BMIb
Low weight (18.5) 31 2.1 3.81 (2.86 to 4.77)
Recommended weight (18.5-24.9) 469 33.6 3.91 (3.34 to 4.48)
Overweight (25.0-29.9) 448 30.4 4.18 (3.43 to 4.92)
Obese I (30.0-34.9) 283 20.0 5.10 (3.97 to 6.24)
Obese II (35) 199 12.2 6.93 (4.39 to 9.47)
Unknown 25 1.6 3.89 (1.86 to 5.92)
Cigarette smoking
Never smokedc 640 48.8 4.37 (3.52 to 5.22)
Former smoker 311 22.6 4.53 (3.82 to 5.24)
Some days 63 4.4 3.72 (3.00 to 4.44)
Every day 264 20.5 5.00 (3.88 to 6.12)
Unknown 177 3.8 6.69 (5.59 to 7.79)
Abbreviations: BMI, body mass index; BPA, bisphenol A; CI, confidence interval; GED, General Educational Development.
aPercentages may not sum to 100 because of rounding.
bCalculated as weight in kilograms divided by height in meters squared.
c Included those who had ever smoked 100 cigarettes.
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number of participants (n=1029) be-
cause of item nonresponse and because
those younger than 20 years were not
questioned. In models including self-
reported daily alcohol consumption, BPA
concentration remained associated with
increasedconcentrationsofGGT(=.06;
95% CI, 0.02 to 0.10; P=.007).
Inmodelsadjusted for triglyceride lev-
els, a 1-SD change in BPA concentra-
tion was associated with increased odds
of reporting cardiovascular disease (OR,
1.41; 95% CI, 1.20 to 1.65;P .001) and
diabetes (OR, 1.38; 95% CI, 1.20 to 1.58;
P .001). Models adjusted for levels of
triglycerides plus LDL-C had a reduced
number of participants (data for the fast-
ing subsample only), but overall trends
were similar: a1-SDincrease inBPAcon-
centration was associated with increased
odds of reporting diabetes (n=635; OR,
1.40;95%CI,1.02 to1.93;P=.04).How-
ever, the association with cardiovascu-
lar disease became nonsignificant,
although the trend was similar (n=546;
OR, 1.22; 95% CI, 0.80 to 1.88; P=.33).
Finally, we found that including mea-
suredconcentrations ofotherphenols (4-
tert-octyl phenol, benzophenone, and tri-
closan) did not affect the relationship
between BPA concentration and dis-
ease or levels of blood analytes, and these
compounds were not themselves asso-
ciated with these outcomes. For ex-
ample, in adjusted models the OR of re-
porting cardiovascular disease associated
with a 1-SD score change in 4-tert-octyl
phenol concentrations was 1.10 (95% CI,
0.79 to 1.54;P=.55) and of reporting dia-
betes was 0.93 (95% CI, 0.64 to 1.36;
P=.71). A 1-SD score change in 4-tert-
octyl phenol concentrations was not as-
sociated with changes in concentra-
tions of the 3 liver enzymes; eg, for GGT,
the  coefficient for 4-tert-octyl phenol
per 1-SD change was 0.00 (95% CI, −0.03
to 0.04; P=.78). In fully adjusted BPA
models with the addition of standard-
ized 4-tert-octyl phenol and triclosan
concentrations, the OR for reporting car-
diovascular disease with a 1-SD score
change in BPA concentration was 1.38
(95% CI, 1.18 to 1.61; P .001) and for
diabetes was 1.40 (95% CI, 1.22 to 1.60).
BPA concentration remained associ-
ated with logged levels of GGT (=.06;
95% CI, 0.03 to 0.10; P=.002).
COMMENT
In this study we aimed to assess whether
increased urinary BPA concentrations
were associated with adverse health ef-
fects in the general US adult popula-
tion. This analysis made use of the first
large-scale and high-quality population-
representative data set to become avail-
able. After adjusting for potential con-
founders, we found that higher BPA
concentrations were associated with di-
agnoses of cardiovascular disease and
diabetes. We also found associations be-
tween higher BPA concentrations and
clinically abnormal concentrations of
the 3 liver enzymes examined, namely
GGT, alkaline phosphatase, and lac-
tate dehydrogenase. Importantly, we
observed no associations with the other
common conditions examined, sug-
gesting specificity of the associations.
A series of sensitivity analyses pro-
vided further support for the specific-
ity of the associations found.
Controversy has surrounded the risk
that BPA poses to humans, because esti-
mates extrapolated from animal stud-
ies32 have demonstrated significant
species-specific differences in both
metabolism and toxicity32 and also
because of the multiple potential routes
of human exposure. Ingestion of oral
doses of BPA in rats and humans leads
to first-pass metabolism in the intestine
and liver to yield the major metabolite,
BPA-monoglucuronide.33 Transdermal
exposureand inhalationof airbornedust
will largely avoid first-pass metabolism,
which isalso limited inneonates.34 While
BPA-monoglucuronide is eliminated in
the bile in rodents, in humans it is elimi-
nated principally in the urine, and both
gastrointestinal tractglucuronidationand
enterohepatic recirculation differ
between rats and humans. Modeling the
pharmacokineticsofBPAis further com-
plicated by a lack of human exposure
studies, which are restricted for ethical
reasons and by the difficulties in find-
ing individuals completelyunexposed to
BPA from the environment. The human
Figure. Estimated Mean Bisphenol A (BPA) Concentrations in Relation to Reported Diseases
and Conditions
0 2 4 6 8 1210 14
Mean BPA Level, ng/mL
Cardiovascular disease
Condition
Coronary heart disease
Stroke
Diabetes
Respiratory disease
Asthma
Bronchitis or emphysema
Cancer
Thyroid disease
Arthritis
Liver disease
Angina
Heart attack
Diagnosis
Reported
Not reported
Estimates adjusted for age and sex. Error bars indicate 95% confidence intervals.
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experimentalexposuresthatdoexisthave
mostly been to single high doses.4 Cal-
culations to predict actual human expo-
sure levels based on animal exposure
studies have reported mean circulating
concentrationsofbothunconjugatedand
conjugated BPA.4
These models suggest that exposure
amongthegeneralUSpopulationis likely
to exceed the 50-µg/kg per day refer-
encedosecurrentlyrecommendedbythe
US Environmental Protection Agency
and that exposure is most likely through
continuous, multiroute exposure, prin-
cipally diet, but also through transder-
mal exposure and inhalation of air-
borne dust. These results confirm
estimatesmadefromearly-morningurine
samplescollectedfrom48women,which
were used to estimate an intake of 0.6 to
71.4 µg/d.35 A study of Japanese univer-
sity students between 1992 and 1999
compared urinary BPA concentrations
withdietary intaketosuggest thatcanned
beverages constitute a major dietary
source.36
Becausehumanhealtheffectsaremost
likely associated with long-term, low-
dose exposure, the relevance of single
measurements of urinary BPA concen-
trations has been questioned. From the
few pharmacokinetic studies of human
BPA metabolism, near-complete uri-
nary excretion has been shown to occur
within 24 hours of a single high dose.37
Mahalingaiah et al38 examined tempo-
ral variability in urinary concentrations
and foundthatalthoughasecondsample
could improve the sensitivity of predict-
ing an individual’s longer-term expo-
sure status, a single urinary measure-
ment showed moderate sensitivity for
Table 2. Odds Ratios of Diseases and Conditions Associated With a 1-SD Increase in Bisphenol A Concentration
Disease/Condition
Unweighted,
No./Total Weighted %
Model 1a Model 2b
OR (95% CI) P Value OR (95% CI) P Value
Arthritis 312/1273 22.98 0.99 (0.77 to 1.28) .96 0.97 (0.78 to 1.21) .75
Cancer 77/1275 6.77 1.12 (0.85 to 1.48) .38 1.14 (0.86 to 1.52) .33
Cardiovascular disease 79/1272 4.76 1.36 (1.16 to 1.60) .001 1.39 (1.18 to 1.63) .001
Angina 42/1274 2.66 1.26 (1.10 to 1.44) .002 1.28 (1.09 to 1.50) .006
Coronary heart disease 46/1276 2.83 1.41 (1.09 to 1.82) .01 1.63 (1.18 to 2.26) .006
Heart attack 42/1277 2.79 1.33 (1.08 to 1.64) .01 1.40 (1.11 to 1.78) .008
Diabetes 136/1455 7.94 1.40 (1.21 to 1.63) .001 1.39 (1.21 to 1.60) .001
Liver disease 55/1274 3.89 0.77 (0.40 to 1.49) .42 0.74 (0.37 to 1.44) .35
Respiratory disease
Asthma 174/1454 12.35 1.02 (0.89 to 1.18) .75 0.98 (0.84 to 1.14) .80
Bronchitis or emphysema 81/1274 6.47 1.03 (0.81 to 1.30) .82 0.98 (0.74 to 1.29) .87
Stroke 40/1278 2.35 0.99 (0.83 to 1.19) .95 0.97 (0.74 to 1.27) .82
Thyroid disease 115/1275 10.03 1.13 (0.89 to 1.43) .30 1.09 (0.88 to 1.37) .40
Abbreviations: CI, confidence interval; OR, odds ratio.
aAdjusted for age, sex, and urinary creatinine concentration.
bAdjusted for age, sex, race/ethnicity, education, income, smoking, body mass index, waist circumference, and urinary creatinine concentration.
Table 3. Linear Regression Coefficients of Logged Analytes Associated With a 1-SD Increase in Bisphenol A Concentrationa
Analyte Unweighted, No.
Model 1b Model 2c
 (95% CI) P Value  (95% CI) P Value
C-reactive protein 1390 0.09 (0.02 to 0.15) .02 0.02 (−0.02 to 0.06) .24
Glucose homeostasis
Insulind 661 0.11 (0.01 to 0.21) .04 0.07 (0.00 to 0.15) .06
Glucosed 655 0.02 (0.00 to 0.03) .02 0.01 (−0.01 to 0.04) .37
HOMA2d
-Cell function 652 0.05 (−0.03 to 0.12) .20 0.03 (−0.01 to 0.07) .09
Insulin resistance 652 0.11 (0.01 to 0.21) .03 0.07 (−0.01 to 0.15) .07
Lipids
LDL-Cd 639 0.00 (−0.05 to 0.05) .93 −0.01 (−0.06 to 0.03) .58
Triglycerides 1376 0.02 (−0.04 to 0.08) .45 0.01 (−0.04 to 0.05) .79
Liver enzymes
Alkaline phosphatase 1378 0.03 (0.02 to 0.05) .001 0.02 (0.01 to 0.04) .01
-Glutamyltransferase 1377 0.08 (0.03 to 0.12) .002 0.06 (0.03 to 0.10) .001
Lactate dehydrogenase 1374 0.02 (0.01 to 0.03) .007 0.01 (0.00 to 0.03) .04
Abbreviations: CI, confidence interval; HOMA2, updated homeostatic model assessment; LDL-C, low-density lipoprotein cholesterol.
aCoefficients represent change in logged analyte level for each 1-SD change in bisphenol A concentration.
bAdjusted for age, sex, and urinary creatinine concentration.
cAdjusted for age, sex, urinary creatinine concentration, race/ethnicity, education, income, smoking, body mass index, and waist circumference.
dLevels were measured in a random subsample assigned to fast; models with these outcomes were weighted to allow for this.
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predicting the individual’s tertile catego-
rization. This temporal variability in uri-
naryBPAconcentrations is likely tohave
resulted in underestimation of the true
strengths of association with the out-
comes in our analyses.
BPA has long been thought to act via
relatively loose binding to the estrogen
receptor,andthismodeofactionhasbeen
incorporated in pharmacokinetic mod-
els; however, recent evidence suggests
that BPA also binds strongly to the estro-
gen-related receptor , the function of
which is unknown.6 Although the major
metabolite BPA-monoglucuronide lacks
estrogenic activity, the generation of
estrogenically active metabolites follow-
ing oxidative cleavage of BPA has been
reported in vitro in rat liver microsomal
fractions,39 although the in vivo signifi-
cance of this pathway is not yet clear.
Bindhumoletal7 foundBPA-inducedoxi-
dative stress in rat hepatocytes with oral
intake over a 30-day period, and hepa-
tocyte damage has been reported in a
number of other experimental con-
texts.8-11 Lipid accumulation has been
shown in adipocyte and hepatoma cell
lines exposed to BPA.40 A variety of other
effects of BPA have been noted, includ-
ing disrupted pancreatic -cell func-
tion, which produces insulin resistance
in mice exposed to oral BPA doses well
below the lowest observed adverse effect
level currently considered by the Envi-
ronmental Protection Agency.12 Four
daysof low-doseBPAinjectionsalsopro-
duced insulin resistance in mice.41
Other studies have identified associa-
tions between environmental toxins,
body weight, and diabetes,42,43 and it has
been proposed that exposure to some en-
vironmentalpollutantsmay initiateorex-
acerbate thedevelopmentofobesity14 and
associated health problems.44 We found
an apparently wide range of BPA con-
centrations across BMI categories, with
weighted but unadjusted mean BPA con-
centrations of 3.91 ng/mL (95% CI, 3.34
to 4.48) in participants with BMI of 18.5
to 24.9 compared with 6.93 ng/mL (95%
CI 4.39 to 9.47) in those with BMI of 35
or more (Table 1). However, formal
testing of logged BPA concentrations ad-
justed for age, sex, and urinary creati-
nine concentrations showed no signifi-
cant differences between the categories
(data available from the authors on re-
quest). Although a possible explana-
tion for our findings is that the in-
creased dietary intakes associated with
obesity also result in higher intakes of
BPA and consequent morbidity, the ob-
served disease and liver enzyme changes
were present after adjusting for both BMI
and waist circumference. Crucially, the
association with GGT was present after
excluding overweight and obese partici-
pants. An association of BPA concentra-
tion with GGT concentration also was
present in those without cardiovascular
disease or diabetes, suggesting that “re-
verse causation” (in which the pres-
ence of these diseases might have led to
greater exposure or to some form of al-
tered BPA excretion) is also unlikely.
Exposure to BPA also might be an in-
dicator of exposure to multiple xenobi-
otics, including other endocrine disrup-
tors—but, as presented, adjustment for
other environmental phenols and known
xenoestrogens including4-tert-octylphe-
nol and triclosan made no difference to
the observed outcomes, suggesting a spe-
cific effect mediated by BPA. We also
have explored a range of alternative ap-
proaches to accounting for the sam-
pling design, the distribution of BPA con-
centrations, and the correction of urinary
creatinine concentrations (see eSupple-
ment at http://www.jama.com), all of
which point to our results being robust.
The main limitation of our analyses is
their cross-sectional nature: longitudi-
nal data demonstrating that high BPA
concentrations predict later onsets of bio-
chemical change or diagnoses would
strengthen the evidence. A further limi-
tation is that we have examined a broad
hypothesis of associations between
higher BPA concentrations and adverse
effects on health status, including tests
of association with 8 major diagnostic
groupings (with 3 questions each about
cardiovascular and respiratory condi-
tions) and 8 blood-based assays. Our ap-
proach, justified by this being the first
large-scale study, may have resulted in
false-positive associations. Although
false-positive inverse associations be-
tween BPA concentrations and out-
comes were theoretically as likely, none
were found.
Independent replication is now
needed to confirm the associations re-
ported. Because our analyses are based
on urinary concentrations of BPA, which
reflect recent exposure, studies based on
repeat measurements over weeks,
months, or even years would improve the
assessment of longer-term exposure.
Given the many routes of exposure to
BPA, direct measures of dermal contact
or of contact with contaminated foods,
beverages, and dusts would be very dif-
ficult to undertake. A further issue is that
although the previous animal-model lit-
erature provides evidence of the mecha-
nisms underlying effects on liver cells
(and therefore liver enzymes) and insu-
lin signaling (and therefore diabetes, as
previously discussed), the mechanisms
underlying the effect on prevalence of
cardiovascular disease are not obvious.
If the associations reported here are con-
firmed in independent studies, more
work will be needed to identify the
mechanisms of action linking long-
term, low-dose BPA exposure to ad-
verse outcomes in humans. Given the
substantial negative effects on adult
health that may be associated with in-
creased BPA concentrations and also
given the potential for reducing human
exposure, our findings deserve scien-
tific follow-up.
CONCLUSIONS
Using data representative of the adult US
population, we found that higher uri-
nary concentrations of BPA were asso-
ciated with an increased prevalence of
cardiovascular disease, diabetes, and
liver-enzyme abnormalities. These find-
ings add to the evidence suggesting
adverse effects of low-dose BPA in ani-
mals. Independent replication and fol-
low-up studies are needed to confirm
these findings and to provide evidence
on whether the associations are causal.
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